Our highly-skilled teams with proven track record of scaling up expedite robust and cost-effective process development
We understand titer matters and the importance of speed and efficiency for early stage therapeutic protein development.
We adopt the Quality-by-Design (QbD) strategy for process development, together with our extensive know-how and advanced techniques adoption, we are able to efficiently establish the process that will yield the optimal outcome in a cost-effective manner.
We utilize our 3L bioreactors platform for robust process development and scale-up to 50L or 200L manufacturing to support fast track IND-enabling program. We also offer comprehensive services for process characterization to support process validation and marketing authorization application.